BCHOOSE TO VACCINATED. Ask your doctor about the MenB * vaccine.

Similar documents
NeisVac-C Meningococcal group C polysaccharide conjugate vaccine (tetanus toxoid protein conjugate)

IMPORTANT: PLEASE READ

ACT-HIB powder and solvent for solution for injection Haemophilus influenzae type b Conjugate Vaccine

Package leaflet: Information for the user

PACKAGE LEAFLET: INFORMATION FOR THE USER

Help keep hepatitis A and B out of your travel plans.

Vaccine Information Statement: PEDIATRIC VACCINES (Multiple)

Help protect your baby against MenB

Package leaflet: Information for the user

PACKAGE LEAFLET: INFORMATION FOR THE USER

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: information for the user

Package leaflet: Information for the user. Haemophilus type b and Meningococcal group C conjugate vaccine

MENACTRA Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

PRODUCT MONOGRAPH BEXSERO. Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection

Some general information on hepatitis A infection is given at the end of this leaflet.

Protecting your baby against meningitis and septicaemia

Package leaflet: information for the user

If you have any concerns about ENGERIX-B talk to your doctor, nurse or pharmacist.

Which Diseases Should My Child Be Protected Against?

HEALTHCARE SUPPLIES SPECIALISTS. Product information. amaproducts.com.au HEALTHCARE SUPPLIES SPECIALISTS

GARDASIL 9 [Human Papillomavirus 9-valent Vaccine, Recombinant] Consumer Medicine Information

BEXSERO contains the excipients sodium chloride, histidine, sucrose, and water for injections.

Vaccines for Children

Package Leaflet: Information for the user. Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed)

TRIPACEL Pertussis Vaccine-Acellular, Combined with Diphtheria and Tetanus Toxoids (Adsorbed)

Package leaflet: Information for the user Priorix, powder and solvent for solution for injection in a pre-filled syringe

Multicomponent Meningococcal group B Vaccine (recombinant, adsorbed) Pharmacotherapeutic group: Meningococcal vaccines, ATC code: J07AH09.

TABLE OF CONTENTS. In what way can this educational material help me? Why are vaccinations important? Who needs vaccinations?

Vaccines. Bacteria and Viruses:

PRESCRIBER SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR THE HEALTHCARE PROVIDER

เอกสารกาก บยาภาษาอ งกฤษ. AVAXIM 160 U Suspension for injection in a prefilled syringe Hepatitis A vaccine (inactivated, adsorbed)

Yukon School Immunization Program Grade 9 INFORMATION FOR PARENTS/GUARDIANS

PACKAGE LEAFLET: INFORMATION FOR THE USER

A Parent s Guide to Childhood Immunization. Be informed.

Package leaflet: Information for the user

PRODUCT MONOGRAPH BEXSERO. Multicomponent Meningococcal B Vaccine (recombinant, adsorbed) BEXSERO Suspension for Injection

D-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin

PATIENT SAFETY BROCHURE; IMPORTANT SAFETY INFORMATION FOR PATIENTS. Before starting on Soliris Important safety information for patients

Help protect your child. At-a-glance guide to childhood vaccines.

Help protect your child. At-a-glance guide to childhood vaccines.

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. SYLVANT pronounced SILL-vant siltuximab for injection

If you have any concerns about being given this vaccine, ask your doctor or pharmacist.

Before starting on Soliris.

HAVRIX 1440 and HAVRIX Junior

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe

If you have any concerns about being given this vaccine, ask your doctor.

Meningococci and meningococcal disease

ADACEL POLIO. This leaflet answers some common questions about ADACEL POLIO. It does not take the place of talking to your doctor or pharmacist.

Package leaflet: Information for the user. Poliomyelitis Vaccine (Inactivated) suspension for injection in pre-filled syringe

46825 (260) $UPONT

Help protect your child. At-a-glance guide to childhood vaccines.

Combined diphtheria-tetanus-acellular pertussis (dtpa) and Inactivated Poliovirus Vaccine

Package leaflet: Information for the user REPEVAX. Suspension for injection in pre-filled syringe

Community Immunization Education Guide Tool Kit

A Parent s Guide to ImmunIzatIon

Lesson 3: Immunizations

IPOL. Inactivated Poliomyelitis Vaccine. Consumer Medicine Information

UNDERSTANDING THE CORRECT ANSWERS immunize.ca

Frontenac Medical Associates 791 Princess Street, Suite 201 Kingston, ON K7L 1E

Tetanus, Diphtheria and Pertussis (T.D.A.P.) Vaccine: What you need to know.

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]

AUSTRALIAN PRODUCT INFORMATION. BEXSERO (multicomponent meningococcal group b vaccine) suspension for injection

VIVAXIM. Salmonella typhi Vi polysaccharide and inactivated hepatitis A virus antigen vaccine. Consumer Medicine Information

Suspension for injection in pre-filled syringe Diphtheria, tetanus and pertussis (acellular component) vaccine (adsorbed, reduced antigen content)

Immunisation. for babies just after their first birthday

This leaflet answers some common questions about PNEUMOVAX 23 (pronounced new-mo-vax). It does not contain all the available information.

VIVAXIM Salmonella typhi Vi polysaccharide and inactivated hepatitis A virus antigen vaccine

Diphtheria, Tetanus, Pertussis, Polio, Hib and Hepatitis B vaccine for babies and children

Package leaflet: information for the user

VARIVAX Refrigerated Varicella Virus Vaccine Live

NEW ZEALAND DATA SHEET

Grade 7 School Immunization Program

FULL PRESCRIBING INFORMATION

Frequently Asked Questions Vaccine for Teens Program

Package leaflet: Information for the user. Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la] Mepolizumab for Injection

Package leaflet: Information for the user

IMOJEV Japanese encephalitis vaccine (live, attenuated)

Acknowledgements. Introduction. Structure of the video

The Continued Need for Immunizations in Top Ten Causes of Death in the U.S., 1900 vs Common Questions about Vaccines

The Continued Need for Immunizations in 2016

VAQTA Adult, Suspension for injection

For Residence Hall Students Only

How It Spreads Symptoms Can Include Complications

Soliris (eculizumab): Paroxysmal nocturnal haemoglobinuria (PNH) Patient/Parent information brochure

A Parent s Guide to Vaccination

MEDICATION GUIDE. BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use

DUKORAL. Oral inactivated cholera and ETEC vaccine. Consumer Medicine Information. It does not take the place of talking to your doctor or pharmacist.

Don t Wait, Vaccinate!

HEPATYRIX (Combined inactivated hepatitis A and Vi polysaccharide typhoid vaccine) CONSUMER MEDICINE INFORMATION LEAFLET

TYPHIM Vi, Solution for injection

REQUIRED IMMUNIZATIONS

Your guide to understanding childhood immunisation

7 10 YEARS YEARS YEARS

Pregnant? There are many ways to help protect you and your baby. Immunise against: Flu (Influenza) Whooping cough (Pertussis) German measles (Rubella)

Package leaflet: Information for the user

Transcription:

BCHOOSE TO VACCINATED Vaccinate against meningococcal disease caused by Neisseria meningitidis group B strains (MenB) with BEXSERO BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed) is a vaccine for the prevention of meningococcal disease caused by Neisseria meningitidis group B bacteria in individuals from 2 months through 17 years of age. BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains and does not offer protection against strains A, C, Y, and W-135. As with any vaccine, BEXSERO may not fully protect all of those who are vaccinated. BEXSERO does not treat or reduce the consequences of meningococcal meningitidis, including meningitis, sepsis, and death. Ask your doctor about the MenB * vaccine. * MenB is meningococcal disease caused by Neisseria meningitidis group B strains. B vaccinated.

UNDERSTANDING meningococcal disease caused by Neisseria meningitidis group B strains What is meningococcal disease? Meningococcal disease is a rare but potentially serious infection caused by different strains of Neisseria meningitidis also known as meningococcus bacteria. Meningococcus bacteria includes Neisseria meningitidis group B strains. The most common forms of meningococcal disease are: Meningococcal meningitis an infection of the lining of the brain and spinal cord and; Septicemia an infection of the bloodstream. What are the symptoms? Symptoms begin mildly like a cold or flu: fever, headache, aches and pains in joints and muscles. These can progress rapidly into much more severe effects. Although most people fully recover, up to 10% of patients die, typically within 24 to 48 hours after the onset of symptoms. Of those who recover, up to 20% experience serious complications. Meningococcal disease starts quickly and may progress rapidly to cause serious, possibly life-threatening infections. 2

About meningococcal disease caused by Neisseria meningitidis group B strains (MenB) What causes meningococcal disease? Among the different groups of meningococcal bacteria, five A, B, C, W-135 and Y cause the most cases of meningococcal disease. In Canada, the number of cases caused by each group of bacteria varies from year to year. From 2004 to 2007, there was an increase of MenB.* In fact, in 2011, MenB* was the most common form of meningococcal disease in Canadians. In Canada between 2007 and 2011, the average annual incidence (per 100,000 population) of MenB* was highest in: Infants under 1 year of age, followed by Children 1 to 4 years of age, and Adolescents aged 15 to 19 years. How can you help protect your child against meningococcal disease caused by Neisseria meningitidis group B strains? Prevention is the best strategy for combating any infectious disease. Ask your doctor about the MenB * vaccine. BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains and does not offer protection against strains A, C, Y, and W-135. BEXSERO does not treat or reduce the consequences of meningococcal meningitidis, including meningitis, sepsis, and death. As with any vaccine, BEXSERO may not fully protect all of those who are vaccinated. * Men B is meningococcal disease caused by Neisseria meningitidis group B strains. Bexsero is indicated for children 2 months to 17 years of age. 3 B vaccinated.

ABOUT BEXSERO The first and only vaccine to help protect against meningococcal disease caused by Neisseria meningitidis group B strains (MenB) in children 2 months through 17 years of age. What is BEXSERO? BEXSERO is a vaccine for the prevention of meningococcal disease caused by Neisseria meningitidis group B strains. MenB* may lead to serious, and sometimes lifethreatening, infections such as meningitis (infection of the lining of the brain and spinal cord) and sepsis (blood poisoning). How does it work? The vaccine stimulates the body s own immune system to produce antibodies. These antibodies kill Neisseria meningitidis group B bacteria that cause meningococcal disease. If a vaccinated person is infected by these bacteria, their immune system can be prepared to respond and help protect against infection and disease. BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains and does not offer protection against strains A, C, Y, and W-135. As with any vaccine, BEXSERO may not fully protect all of those who are vaccinated. BEXSERO does not treat or reduce the consequences of meningococcal meningitidis, including meningitis, sepsis, and death. Very common adverse events (may affect more than 1 in 10 people) after vaccination with BEXSERO were pain/tenderness at the injection site, redness at the injection site, swelling of the skin at the injection site, hardness at the injection site. In infants and children (less than 2 years of age), fever can occur more frequently when BEXSERO is given at the same time as routine infant vaccines. Allergic reactions may also occur. * Men B is meningococcal disease caused by Neisseria meningitidis group B strains. 4

Recommended vaccination schedule Age group Primary doses Interval between primary doses Booster dose Infants 2 to 5 months of age 3 1 month 1 Required in the second year of life between 12 and 23 months of age. This dose should be given early in the second year of life, whenever possible. Infants 6 to 11 months of age (unvaccinated) 2 2 months 1 Required in the second year of life, after an interval of at least 2 months from the last dose. The need for further doses has not been established. Children 12 months up to 10 years of age * 2 2 months The need for further doses has not been established. Adolescents 11 to 17 years of age 2 1 month The need for further doses has not been established. * The 12 months to 10 years of age population includes unvaccinated children aged 12 months through 23 months. Make sure that your child gets the full vaccination series. This allows your child to get the full benefits of BEXSERO. What if a dose is missed? If you forget to go back to the doctor/pharmacist/ nurse at the scheduled time, ask the doctor/ pharmacist/nurse for advice. Where is BEXSERO administered? BEXSERO will be injected into your child s arm or leg muscle depending on age. Talk to your doctor, pharmacist, or nurse for further information. 5 B vaccinated.

Can BEXSERO be given with other vaccines? BEXSERO can be given at the same time as any of the following vaccine antigens, either as single or as combination vaccines: Diphtheria Tetanus Acellular pertussis (whooping cough) Haemophilus influenzae type b Inactivated polio Hepatitis B Potential side effects and what to do about them. Like all vaccines, BEXSERO may cause side effects. When BEXSERO is administered, the most frequent side effects (more than 1 in 10 people) your child may get (reported in all age groups 2 months to 17 years of age) are pain/tenderness at the injection site, redness of the skin at the injection site, swelling at the injection site, hardness of the skin at the injection site. Infants and children (up to 10 years of age) Very common (may affect more than 1 in 10 people) Fever ( 38 C) Loss of appetite Tenderness or discomfort at the injection site (including severe injection site tenderness resulting in crying when injected limb is moved) High fever ( 40 C) Seizures (including febrile seizures) Heptavalent pneumococcal conjugate Measles Mumps Rubella Chickenpox When BEXSERO is given at the same time as any of the vaccines listed above, the vaccines must be given at separate sites. Skin rash (uncommon after booster) Sleepiness Feeling irritable Unusual crying Vomiting Diarrhea Uncommon (may affect up to 1 in 100 people) Vomiting (after booster) Dry skin, itchy rash, skin rash Paleness (rare after booster) 6

Rare (may affect up to 1 in 1,000 people) Kawasaki disease which may include symptoms such as fever that lasts for more than five days, associated with a skin rash on the trunk of the body, and sometimes followed by a peeling of the skin on the hands and fingers, swollen glands in the neck, red eyes, lips, throat and tongue. Your doctor, pharmacist or nurse may ask you to give your child medicines that help lower fever at the time, and after, BEXSERO has been administered. This may help reduce some of the side effects of BEXSERO. Individuals from 11 years of age and older Very common (may affect more than 1 in 10 people) Pain at the injection site resulting in inability to perform normal daily activity Painful muscles and joints Nausea Generally feeling unwell Headache If any of the noted side effects becomes serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, pharmacist or nurse immediately. Side effects that have been reported during marketed use include: Allergic reactions may include severe swelling of the lips, mouth, throat (which may cause difficulty in swallowing), difficulty breathing with wheezing or coughing, rash, loss of consciousness and very low blood pressure; feeling faint or fainting; blisters at or around the injection site. If any of the noted side effects becomes serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, pharmacist, or nurse immediately. This is not a complete list of side effects. For any unexpected effects while taking BEXSERO, contact your doctor, pharmacist, or nurse. 7 B vaccinated.

WARNINGS AND PRECAUTIONS BEFORE your child receives BEXSERO, talk to your doctor, pharmacist, or nurse if: They have a severe infection with a high temperature. If so, then vaccination will be postponed. The presence of a minor infection, such as a cold, should not require postponement of the vaccination, but talk to your doctor, pharmacist, or nurse first. They are pregnant or breast feeding, or think they may be pregnant or are planning to have a baby. Ask your doctor, pharmacist, or nurse for advice before BEXSERO is given. They have hemophilia or any other condition that may slow down the clotting of the blood, such as treatment with blood thinners (anticoagulants). They have an allergy to the antibiotic kanamycin or to latex. If present, the kanamycin level in the vaccine is low. If you or your child may have allergy to kanamycin, talk to your doctor, pharmacist, or nurse first. Fainting, feeling faint or other stress-related reactions can occur as a response to any needle injection. Tell your doctor, pharmacist, or nurse if they have ever experienced this kind of reaction. BEXSERO should not be used if your child is allergic (hypersensitive) to the active substances or any of the other components of the vaccine closure of BEXSERO. If your child has a weakened immune system, it is possible that the effectiveness of BEXSERO is reduced. As with any vaccine, BEXSERO may not fully protect all of those who are vaccinated. Additionally, BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains and doesn t protect against strains A, C, Y and W-135. 8

When BEXSERO should not be used. BEXSERO should not be used if your child is allergic (hypersensitive) to the active substances or any of the other ingredients of BEXSERO. Medicinal ingredients in BEXSERO The active substances are: 50 μg of recombinant Neisseria meningitidis group B NHBA fusion protein 50 μg of recombinant Neisseria meningitidis group B NadA protein 50 μg of recombinant Neisseria meningitidis group B fhbp fusion protein 25 μg of Outer Membrane Vesicles Neisseria meningitidis group B strain NZ98/254 Antigens are absorbed on aluminum hydroxide (0.5 mg aluminum). Non-medicinal ingredients in BEXSERO The important non-medicinal ingredients are: Sodium chloride, histidine, sucrose, water for injections. Talk to your doctor, pharmacist, or nurse for additional information. 9 B vaccinated.

Important information about BEXSERO You are advised to discuss the advantages and disadvantages of BEXSERO with your healthcare professional before receiving the vaccine. Full product information can be found on myg.sk/bexsero. Reporting an Adverse Event: Your own healthcare professional is the best source of information regarding your health. If you need to report an adverse event, please call 1-800-387-7374. WHERE CAN I GET BEXSERO? BEXSERO is administered at doctors offices and in vaccination clinics. Is the cost of BEXSERO covered? The cost of BEXSERO may be covered by your private insurance. Contact your insurance provider and give the DIN (drug identification number) below to find out: BEXSERO DIN: 02417030 10

Your Child s Vaccination Schedule Step 1: Talk to your doctor about vaccinating your child with BEXSERO. Step 2: Make an appointment for your child s first dose of BEXSERO and note it below under Date. Step 3: Bring it with you to your child s first dose so your doctor, pharmacist, or nurse can write down the dates and times of the following appointments. Infants under 1 year of age Date Time Location Dose 1 Dose 2 Dose 3 Dose 4 (Only required for infants aged 2 to 5 months) Children and Adolescents 1 to 17 years of age Date Time Location Dose 1 Dose 2 If the date has not been set for a dose, use the Date column to note when you are expected to call to schedule the appointment. Don t forget! Also bring your child s vaccination booklet to each appointment to keep it up to date. 11 B vaccinated.

HELP PROTECT YOUR CHILD AGAINST MENINGOCOCCAL DISEASE CAUSED BY NEISSERIA MENINGITIDIS GROUP B STRAINS (MenB)B ASK YOUR DOCTOR ABOUT THE MenB*VACCINE. BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed) is a vaccine for the prevention of meningococcal disease caused by Neisseria meningitidis group B bacteria in individuals from 2 months through 17 years of age. BEXSERO is not expected to provide protection against all circulating meningococcal serogroup B strains and does not offer protection against strains A, C, Y, and W-135. As with any vaccine, BEXSERO may not fully protect all of those who are vaccinated. BEXSERO does not treat or reduce the consequences of meningococcal meningitidis, including meningitis, sepsis, and death. Very common adverse events (may affect more than 1 in 10 people) after vaccination with BEXSERO were pain/tenderness at the injection site, redness at the injection site, swelling of the skin at the injection site, hardness at the injection site. In infants and children (less than 2 years of age), fever can occur more frequently when BEXSERO is given at the same time as routine infant vaccines. Allergic reactions may also occur. Discuss the advantages and disadvantages of BEXSERO with your healthcare professional in advance of receiving the vaccine. Full product information can be found on myg.sk/bexsero. To report an adverse event, please call 1-800-387-7374. Visit bexsero.ca Member of Innovative Medicines Canada * Men B is meningococcal disease caused by Neisseria meningitidis group B strains. BEXSERO is a registered trademark of GlaxoSmithKline Biologicals SA, used under license by GlaxoSmithKline Inc. 2016 GlaxoSmithKline Inc. All rights reserved. B vaccinated. 01423 07/16